{"id":"standard-of-care-thromboprophylaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This refers to conventional thromboprophylaxis regimens (typically anticoagulants such as enoxaparin, unfractionated heparin, warfarin, or direct oral anticoagulants, or antiplatelet agents) used to prevent venous or arterial thromboembolism in at-risk patients. The specific mechanism depends on the agent used but generally involves inhibition of coagulation cascade factors or platelet aggregation.","oneSentence":"Standard of Care thromboprophylaxis prevents blood clot formation through established anticoagulant or antiplatelet mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:26.874Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis in hospitalized patients"},{"name":"Surgical thromboprophylaxis"},{"name":"Atrial fibrillation stroke prevention"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT07411768","phase":"NA","title":"Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2026-03","conditions":"Transcatheter Aortic Valve Replacement, Transcatheter Heart Valve Thrombosis, Anti-inflammatory Therapy","enrollment":116},{"nctId":"NCT06939803","phase":"NA","title":"AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-12-17","conditions":"Venothromboembolism","enrollment":2236},{"nctId":"NCT07384598","phase":"NA","title":"Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.","status":"NOT_YET_RECRUITING","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2026-02-01","conditions":"Thromboprophylaxis, Critical Illness, Intensive Care (ICU)","enrollment":60},{"nctId":"NCT06628778","phase":"PHASE3","title":"Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP)","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2026-10-31","conditions":"Venous Thromboembolism (VTE)","enrollment":802},{"nctId":"NCT07243080","phase":"PHASE4","title":"Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","status":"RECRUITING","sponsor":"Mayo Hospital Lahore","startDate":"2025-10-10","conditions":"Deep Venous Thromboses, Laparotomy Patients","enrollment":212},{"nctId":"NCT01588171","phase":"NA","title":"Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2012-05","conditions":"Venous Thromboembolic Diseases","enrollment":7020},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT06523959","phase":"PHASE4","title":"Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial","status":"RECRUITING","sponsor":"Clinical Urology and Epidemiology Working Group","startDate":"2024-06-06","conditions":"Venous Thromboembolism, Bleeding","enrollment":5436},{"nctId":"NCT05245877","phase":"PHASE4","title":"Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2022-08-17","conditions":"Pancreas Cancer, Pancreas Neoplasm, Surgery","enrollment":800},{"nctId":"NCT03532139","phase":"PHASE2","title":"Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-07-25","conditions":"Ovarian Cancer","enrollment":24},{"nctId":"NCT06611319","phase":"PHASE3","title":"ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty","status":"RECRUITING","sponsor":"Prof. Stavros Konstantinides, MD","startDate":"2024-11-26","conditions":"Hip Arthroplasty, Total, Prevention of Venous Thromboembolism","enrollment":2932},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03506815","phase":"PHASE3","title":"Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2019-03-15","conditions":"Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis, Cancer","enrollment":105},{"nctId":"NCT04243122","phase":"PHASE2","title":"Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-02-17","conditions":"Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET), JAK2 Mutation","enrollment":44},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT02984384","phase":"PHASE3","title":"PREVENTion of Clot in Orthopaedic Trauma","status":"COMPLETED","sponsor":"Major Extremity Trauma Research Consortium","startDate":"2017-04-24","conditions":"Blood Clot, Trauma","enrollment":12424},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT06246604","phase":"NA","title":"Screening for Deep Vein Thrombosis in Intensive Care","status":"UNKNOWN","sponsor":"University Of Perugia","startDate":"2023-11-01","conditions":"Deep Vein Thrombosis","enrollment":1300},{"nctId":"NCT05040776","phase":"PHASE2","title":"COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients","status":"WITHDRAWN","sponsor":"eXIthera Pharmaceuticals","startDate":"2023-10","conditions":"Thrombopenia, Covid19","enrollment":""},{"nctId":"NCT04360824","phase":"PHASE4","title":"Covid-19 Associated Coagulopathy","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2020-05-06","conditions":"COVID 19 Associated Coagulopathy","enrollment":176},{"nctId":"NCT04655586","phase":"PHASE2, PHASE3","title":"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19","status":"COMPLETED","sponsor":"ARCA Biopharma, Inc.","startDate":"2020-12-10","conditions":"Covid19","enrollment":160},{"nctId":"NCT04401410","phase":"PHASE1","title":"Anti-SARS Cov-2 T Cell Infusions for COVID 19","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2020-11-04","conditions":"SARS-CoV 2, Viral Infection, COVID 19","enrollment":4},{"nctId":"NCT04492254","phase":"PHASE3","title":"Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Thrombosis Research Institute","startDate":"2020-10-27","conditions":"COVID-19","enrollment":219},{"nctId":"NCT04416048","phase":"PHASE2","title":"Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2020-11-30","conditions":"COVID-19","enrollment":111},{"nctId":"NCT04345848","phase":"PHASE3","title":"Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","status":"TERMINATED","sponsor":"University Hospital, Geneva","startDate":"2020-04-28","conditions":"COVID, Sars-CoV2","enrollment":160},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04201626","phase":"NA","title":"Adapted ERAS in Gynecologic Oncology Surgery","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-06-01","conditions":"Genital Neoplasm Malignant Female","enrollment":200},{"nctId":"NCT02366871","phase":"PHASE2","title":"Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-04-28","conditions":"Gynecologic Cancer, Venous Thromboembolism","enrollment":400},{"nctId":"NCT02396732","phase":"PHASE4","title":"Aspirin and Enoxaparin for VTE in Trauma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2016-02","conditions":"Venous Thromboembolism, Thromboprophylaxis, Trauma","enrollment":31},{"nctId":"NCT03986450","phase":"NA","title":"ERAS Protocol in Laparoscopic Hysterectomy","status":"UNKNOWN","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2019-06-20","conditions":"Surgery","enrollment":60},{"nctId":"NCT01050153","phase":"NA","title":"The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2010-03","conditions":"Venous Thromboembolism","enrollment":50},{"nctId":"NCT01589393","phase":"NA","title":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)","status":"COMPLETED","sponsor":"McMaster University","startDate":"2010-09","conditions":"Traumatic Intracranial Haemorrhage","enrollment":52},{"nctId":"NCT03299296","phase":"PHASE3","title":"Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin","status":"UNKNOWN","sponsor":"Ahmed AbdelMoneim Hassan Ali","startDate":"2017-01-01","conditions":"Thromboses, Deep Vein, Surgery--Complications","enrollment":100},{"nctId":"NCT00634907","phase":"NA","title":"Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)","status":"COMPLETED","sponsor":"Gwen McMillin","startDate":"2006-09","conditions":"Venous Thromboembolism, Bleeding","enrollment":263},{"nctId":"NCT02260908","phase":"NA","title":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage - Pilot Study","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2014-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":300},{"nctId":"NCT00967148","phase":"NA","title":"Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2009-06","conditions":"Deep Vein Thrombosis, Pulmonary Embolism, Cancer","enrollment":18},{"nctId":"NCT00726570","phase":"NA","title":"Alterations of Blood Clotting With the Use of Sequential Compression Devices on the Lower Limbs","status":"TERMINATED","sponsor":"University of Parma","startDate":"2008-08","conditions":"Coagulation, Blood, Compression Devices, Intermittent Pneumatic, Postoperative Complications","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":312,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Standard of Care thromboprophylaxis","genericName":"Standard of Care thromboprophylaxis","companyName":"University of Iowa","companyId":"university-of-iowa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard of Care thromboprophylaxis prevents blood clot formation through established anticoagulant or antiplatelet mechanisms. Used for Venous thromboembolism prophylaxis in hospitalized patients, Surgical thromboprophylaxis, Atrial fibrillation stroke prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}